BRVE Braveheart Bio Inc revenue, earnings and financials
For the quarter ended June 30, 2026, Braveheart Bio Inc reported revenue of n/a, net income of −$15.0M and diluted EPS of −$2.51.
BRVE quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$15.0M, EPS −$2.51
- Quarter ended Mar 31, 2026: revenue n/a, net income −$14.3M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$381K, EPS −$0.14
- Quarter ended Mar 31, 2025: revenue n/a, net income −$99.0K, EPS n/a
BRVE balance sheet
- Jun 30, 2026: cash $123M, total assets $127M, total liabilities $9.34M, shareholders' equity −$95.9M
- Dec 31, 2025: cash $89.2M, total assets $89.4M, total liabilities $5.33M, shareholders' equity −$65.9M